Nutshell Therapeutics announced that NTS231, its independently developed covalent allosteric molecular glue degrader targeting NRF2, has received an IND clearance from the U.S. Food and Drug Administration (FDA), permitting clinical trials in the United States. NTS231 is the first such drug in China and the second globally with this target mechanism to enter the clinical stage.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | FDA (United States) |
| Filing Outcome | IND cleared – clinical trials authorized in the U.S. |
| Product | NTS231 – covalent allosteric molecular glue degrader |
| Company | Nutshell Therapeutics |
| Mechanism Class | KEAP1‑binding molecular glue inducing NRF2 degradation |
| Distinction | First in China, second globally with same target mechanism in clinic |
| Clearance Date | 17 Sep 2026 |
| Planned Trial Design / Indication | Not disclosed |
Drug Profile & Mechanism of Action
- Modality: A high‑activity, high‑selectivity allosteric molecular glue that covalently binds KEAP1 and induces NRF2 protein degradation — a protein‑degradation approach to a transcription factor traditionally considered undruggable by inhibition alone.
- Covalent Anchor: NTS231 irreversibly links to the Cys151 cysteine residue of the KEAP1 protein.
- Conformational Mechanism: The covalent bond stabilizes KEAP1’s spatial conformation in a state that favors interaction with CUL3, promoting formation of a functional KEAP1–CUL3 E3 ubiquitin ligase complex.
- Degradation Outcome: The assembled ligase drives NRF2 degradation, blocking the NRF2 signaling pathway and thereby suppressing cancer cell survival capability.
- Discovery Engine: Developed on Nutshell’s AI‑driven allosteric drug discovery platform ALLOSTAR™, fusing computer‑aided drug design (CADD) with medicinal chemistry to achieve highly specific covalent KEAP1 binding.
- Selectivity: The molecule high‑selectively degrades NRF2, effectively inhibiting the growth of NRF2‑dependent tumors.
Target Rationale – NRF2 Pathway Aberrations in Solid Tumors
- Mutation Prevalence: In solid tumors, loss‑of‑function (LOF) mutations of KEAP1 and CUL3 and gain‑of‑function (GOF) mutations of NRF2 are widespread across multiple cancer types.
- Highest‑Frequency Cancers: These pathway aberrations are especially prominent in lung squamous cell carcinoma (>30%) and lung adenocarcinoma (>20%) — defining large, genetically identifiable patient populations.
- Biological Logic: Constitutive NRF2 activation, driven by KEAP1/CUL3 loss or NRF2 gain, fuels cancer cell survival, chemoresistance, and radioresistance — making NRF2 degradation via restored KEAP1–CUL3 ligase function a mechanistically differentiated strategy.
Preclinical Evidence
| Study Type | Models | Result |
|---|---|---|
| In Vivo Efficacy (monotherapy) | CDX and PDX models – lung squamous cell carcinoma, esophageal squamous cell carcinoma, head & neck squamous cell carcinoma with NRF2/KEAP1/CUL3 mutations or aberrant NRF2 pathway activation | Dose‑dependent antitumor efficacy across all models |
| Combination with Chemotherapy | Multiple KEAP1‑mutant, chemotherapy‑resistant lung squamous cell carcinoma PDX models – NTS231 + paclitaxel | Synergistic enhancement preliminarily demonstrated |
| GLP Toxicology | 28‑day GLP studies in rats and dogs | Good safety profile with a very large safety margin |
Beyond significant monotherapy efficacy, NTS231 is positioned for combination with chemotherapy, various targeted therapies, and ADCs. The 28‑day GLP toxicology results in both rats and dogs provide strong support for subsequent clinical development.
Company Profile & Market Impact
- Company: Nutshell Therapeutics is a biotech developing small molecules against undruggable targets using AI + allosteric mechanisms, founded by Professor Zhang Jian, a world‑leading scientist in the field.
- Financing Momentum: Just this week, the company announced completion of a Series C1 financing of tens of millions of USD — investor backing that precedes the clinical‑stage transition.
- First‑in‑China Positioning: As the first Chinese and second global NRF2‑mechanism molecular glue degrader in clinic, NTS231 places Nutshell at the frontier of both the molecular glue degradation and NRF2‑pathway oncology frontiers, where KEAP1‑mutant lung cancers represent a substantial and genetically stratified market.
- Next Catalysts: First‑in‑human trial initiation, indication selection within KEAP1/NRF2/CUL3‑aberrant solid tumors, and combination‑strategy development — details not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development of NTS231, including its degradation mechanism, combination potential, and application in NRF2‑pathway–aberrant tumors. IND clearance does not guarantee clinical success or eventual approval. Preclinical efficacy in CDX/PDX models and GLP toxicology findings may not translate into human benefit. Actual results may differ materially due to scientific, clinical, regulatory, and competitive risks.-Fineline Info & Tech
